- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00399568
Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery
Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel, Multiple-Dose Study of the Analgesic Efficacy and Safety of IV Acetaminophen (APAP) Versus Placebo Over 48 Hours(Hrs) for the Treatment of Postoperative Pain After Gynecologic Surgery
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35249
- University of Alabama (Anesthesiology)
-
Sheffield, Alabama, États-Unis, 35660
- Helen Keller Hospital
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85032
- Precision Trials
-
Phoenix, Arizona, États-Unis, 85023
- Arizona Research Center, Inc (JC Lincoln)
-
Phoenix, Arizona, États-Unis, 85023
- Arizona Research Center, Inc. (Arrowhead)
-
-
California
-
Arcadia, California, États-Unis, 91007
- Arcadia Methodist Hospital
-
Glendale, California, États-Unis, 91206
- Glendale Adventist Medical Center
-
Pasadena, California, États-Unis, 91105
- Huntington Memorial Hospital
-
San Clemente, California, États-Unis, 92672
- Accurate Clinical Trials, Inc.
-
-
Florida
-
Boynton Beach, Florida, États-Unis, 33414
- Visions Clinical Research
-
Fort Pierce, Florida, États-Unis, 34950
- G and G Research, Inc.
-
Holly Hill, Florida, États-Unis, 32117
- Century Clinical Research, Inc
-
Inverness, Florida, États-Unis, 34452
- Nature Coast Clinical Research
-
Miami, Florida, États-Unis, 33136
- University of Miami School of Medicine Dept. of Anesthesiology
-
Vero Beach, Florida, États-Unis, 32960
- Treasure Coast Obstetrics and Gynecology
-
-
Michigan
-
Royal Oak, Michigan, États-Unis, 48073
- William Beaumont Hospital
-
-
New Jersey
-
Camden, New Jersey, États-Unis, 08103
- Cooper Anesthesia
-
New Brunswick, New Jersey, États-Unis, 08901
- St. Peters University Hospital, Anesthesiology
-
-
New York
-
Albany, New York, États-Unis, 11208
- Albany Medical College Dept. of Anesthesiology
-
Bronx, New York, États-Unis, 10461
- Jacobi Medical Center (Albert Einstein College of Medicine)
-
New York, New York, États-Unis, 10021
- Weill Medical College
-
Stony Brook, New York, États-Unis, 11794
- Stony Brook Anesthesiology Health Sciences Cente
-
-
Ohio
-
Columbus, Ohio, États-Unis, 43210
- The Ohio State University Medical Center
-
-
Pennsylvania
-
Altoona, Pennsylvania, États-Unis, 16602
- Allegheny Pain Managment
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Thomas Jefferson University Dept. of Anesthesiology
-
-
Texas
-
Houston, Texas, États-Unis, 77024
- Memorial Herman/Memorial City Hospital
-
Houston, Texas, États-Unis, 77024
- Texas Woman's Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Undergo gynecologic surgery using standard abdominal approach such as midline or Pfannenstiel incision
- 18-75 years of age
- Body Mass Index (BMI) between 19-45
- American Society of Anesthesiologists (ASA) risk class of I, II, III
- Not have received neuraxial (spinal or epidural) opioid analgesics prior to or during surgery
- Moderate to Severe pain at rest
Exclusion Criteria:
- Requires any additional surgical procedures either related or unrelated to gynecologic surgery during same hospitalization
- Procedures involving only minimal incisions such as laparotomy, laparoscopy, supraumbilical or Maylard incisions
- Has know hypersensitivity to opioids, acetaminophen, or the excipients of IV acetaminophen
- Known history of alcohol or drug abuse or misuse
- Has impaired liver function Aspartate transaminase(AST), Alanine aminotransferase(ALT), bilirubin greater than or equal to 2 times upper limit of normal
- Has significant medical disease(s), or conditions that may contraindicate participation in the study
- Has participated in another clinical trial within 30 days of surgery
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: IV acetaminophen 1 g/100 mL solution
|
Intravenous acetaminophen 1 g/100 mL
Autres noms:
|
Comparateur placebo: IV Placebo 100 mL solution
|
IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Sum of Pain Intensity at Rest-Baseline to 24 Hours (SPI24rest), 1 Gram IV Acetaminophen vs. Placebo.
Délai: Baseline (just prior to the first dose) through 24 hours
|
The Sum of Pain Intensity (SPI) score incorporates the analgesic effects on pain intensity (PI) from Baseline to 24 hours.
SPI was measured by the 100 millimeter (mm) long Visual Analog Scale (VAS) over 24 hours after treatment.
Subjects were asked to mark the level of pain they were experiencing at a certain timepoint on the scale The 100mm VAS scale was used with the left terminus (0 mm) of the scale "No Pain" and the right terminus (100 mm) with "Worst Pain Imaginable".
The range of measurement is 0-2400 mm for 24 hours.
|
Baseline (just prior to the first dose) through 24 hours
|
Sum Pain Intensity at Rest-Baseline to 48 Hours (SPI48rest), 1 Gram IV Acetaminophen vs. Placebo
Délai: Baseline (just prior to the first dose) through 48 hours
|
The Sum of Pain Intensity (SPI) score incorporates the analgesic effects on pain intensity (PI) from Baseline to 48 hours.
SPI was measured by the 100 millimeter (mm) long Visual Analog Scale (VAS) over 48 hours after treatment.
Subjects were asked to mark the level of pain they were experiencing at a certain timepoint on the scale The 100 mm VAS scale was used with the left terminus (0 mm) of the scale "No Pain" and the right terminus (100 mm) with "Worst Pain Imaginable".
The range of measurement is 0-4800 mm for 48 hours.
|
Baseline (just prior to the first dose) through 48 hours
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Subjects Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)
Délai: First dose through 7 day follow up
|
Number of subjects who experienced at least one treatment emergent adverse event (TEAE) A TEAE is an adverse event that occurs on or after administration of the first dose of study medication (T0)
|
First dose through 7 day follow up
|
Subjects Who Experienced at Least One Treatment-emergent Serious Adverse Event.
Délai: 32 days following first dose of study medication.
|
Number of subjects who reported SAEs during the study. A serious Adverse event (SAE) is defined as any untoward medical occurence at any dose of study medication that: Results in Death, Is Life Threatening, Requires inpatient hospitalization or causes prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, or Is an important medical event |
32 days following first dose of study medication.
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CPI-APA-301
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Douleur postopératoire
-
Evergrain, LLCINQUIS Clinical Research Ltd.ComplétéSatiété du pain riche en fibres et riche en protéinesCanada
-
Tel-Aviv Sourasky Medical CenterWeizmann Institute of ScienceComplétéChangements de poids corporel | Modification alimentaire | Microbiote gastro-intestinal | Pain | Tests hématologiquesIsraël
-
University of BergenUniversity of Leipzig; Chalmers University of Technology; Nofima; Paderborn UniversityComplétéHyperglycémie | Prédiabète | Contrôle glycémique | PainNorvège
-
Ege UniversityComplétéObésité | Index glycémique | Glucose sanguin | PainTurquie
Essais cliniques sur IV Acetaminophen
-
Healthgen Biotechnology Corp.RecrutementEmphysème secondaire à un AATD congénitalÉtats-Unis
-
Healthgen Biotechnology Corp.ComplétéAscite HépatiqueÉtats-Unis
-
Eli Lilly and CompanyComplété
-
Eli Lilly and CompanyComplétéMaladie d'AlzheimerÉtats-Unis, Japon
-
C. R. BardComplétéComplication de l'accès vasculaireÉtats-Unis
-
Flame BiosciencesRetiréCancer de l'estomac | Tumeur solide | Cancer du pancréas
-
Prometheus Biosciences, Inc., a subsidiary of Merck...Altasciences Company Inc.ComplétéEn bonne santéÉtats-Unis
-
Alexion Pharmaceuticals, Inc.Syneos HealthComplété
-
Eli Lilly and CompanyComplété
-
Kyowa Kirin Co., Ltd.RésiliéLa dermatite atopiqueJapon